Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?

Revista Portuguesa de Pneumologia (English Edition)

Volumn 22, Issue 6, 2016, Pages 308-314

  Pereira, J M ^a,b   Azevedo, A ^a,b   Basilio C ^a   Sousa Dias, C ^a   Mergulhao P ^a,b   Paiva, J A ^a,b  

^a Universidade do Porto   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Biomarkers; Critically ill patients; Outcome; Proadrenomedullin; Severe community acquired pneumonia

Indexed keywords

ANTIBIOTIC AGENT; PROADRENOMEDULLIN; ADRENOMEDULLIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; FEMALE; HUMAN; LEGIONELLA PNEUMOPHILA; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIA; VERY ELDERLY; BACTERIAL PNEUMONIA; BLOOD; COMMUNITY ACQUIRED INFECTION; CRITICAL ILLNESS; INTENSIVE CARE UNIT; MIDDLE AGED; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOMARKERS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85005949310     PISSN: None     EISSN: 21735115     Source Type: Journal    
DOI: 10.1016/j.rppnen.2016.03.012     Document Type: Article

References (31)

1. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275:134-41, http://dx.doi.org/10.1001/jama.1996.03530260048030
2. Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005;128:2238-46, http://dx.doi.org/10.1378/chest.128.4.2238
3. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140-5, http://dx.doi.org/10.1378/chest.125.6.2140
4. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia. Use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med. 2002;166:717-23, http://dx.doi.org/10.1164/rccm.2102084
5. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med. 1998;158:1102-8, http://dx.doi.org/10.1164/ajrccm.158.4.9803114
6. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50, http://dx.doi.org/10.1056/NEJM199701233360402
7. Rodríguez A, Mendia A, Sirvent J-M, Barcenilla F, de la Torre MV, Solé-Violán J, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007;35:1493-8, http://dx.doi.org/10.1097/01.CCM.0000266755.75844.05
8. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community acquired pneumonia: etiology, prognosis and treatment. Am Rev Respir Dis. 1990;142:369-73, http://dx.doi.org/10.1164/ajrccm/142.2.369
9. Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis R, Cobo E, et al. Severe community acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis. 1991;144:312-8, http://dx.doi.org/10.1164/ajrccm/144.2.312
10. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community acquired pneumonia: etiology, epidemiology and prognostic factors. Chest. 1994;105:1487-95, http://dx.doi.org/10.1378/chest.105.5.1487
11. Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care. 2006;10:R96-103, http://dx.doi.org/10.1186/cc4955
12. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, et al. Midregional proadrenomedullin as a prognostic tool in community acquired pneumonia. Chest. 2009;136:823-31, http://dx.doi.org/10.1378/chest.08-1981
13. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14:R106, http://dx.doi.org/10.1186/cc9055
14. Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrino Metab. 1996;81:1449-53, http://dx.doi.org/10.1210/jcem.81.4.8636349
15. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 2001;22:1693-711, http://dx.doi.org/10.1016/S0196-9781(01)00513-7
16. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000;66:855-72, http://dx.doi.org/10.1016/S0024-3205(99)00358-6
17. Kato J, Tsuruda T, Kitamura K, Eto T. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res. 2003;26:S113-9, http://dx.doi.org/10.1291/hypres.26.S113
18. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369-72, http://dx.doi.org/10.1016/j.peptides.2004.06.019
19. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, et al. Cardiovascular and inflammatory biomarkers to predict shortand long-term survival in community-acquired pneumonia. Am J Respir Crit Care Med. 2010;182:1426-34, http://dx.doi.org/10.1164/ajrccm.201003-0415OC
20. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Disease Society of American/American Thoracic Society consensus guidelines for the management of community acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27-72, http://dx.doi.org/10.1086/511159
21. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-63, http://dx.doi.org/10.1001/jama.1993.03510240069035
22. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10
23. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009;37:456-62, http://dx.doi.org/10.1097/CCM.0b013e318194b021
24. Miguel D, Prieto B, Costa M, Coto D, Alvarez FV. Cord blood plasma reference intervals for potential sepsis markers: pro-adrenomedullin, pro-endothelin and proatrial natriuretic peptide. Clin Biochem. 2011;44:337-41, http://dx.doi.org/10.1016/j.clinbiochem.2010.12.012
25. Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with communityacquired pneumonia. Swiss Med Wkly. 2012;142:w13542, http://dx.doi.org/10.4414/smw.2012.13542
26. Apkinar S, Rollas K, Alagöz A, Segmen F, Sipit T. Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia. J Thorac Dis. 2014;6:921-9, http://dx.doi.org/10.3978/j.issn.2072-1439.2014.06.42
27. Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care. 2014;18:R34, http://dx.doi.org/10.1186/cc13731
28. Travaglino F, De Berardinis B, Magrini L, Bongiovanni C, Candelli M, Silveri NG, et al. Utility of procalcitonin (PCT) and mid regional pro-adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score. BMC Infect Dis. 2012;12:184, http://dx.doi.org/10.1186/1471-2334-12-184
29. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9:R816-24, http://dx.doi.org/10.1186/cc3885
30. Courtais C, Kuster N, Dupuy AM, Folschveiller M, Treige R, Bargnoux AS, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med. 2013;31:215-21, http://dx.doi.org/10.1016/j.ajem.2012.07.017
31. Al Shuaibi M, Bahu RR, Chaftari AM, Wohoush IA, Shomali W, Jiang Y, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis. 2013;56:943-50, http://dx.doi.org/10.1093/cid/cis1029.